Comparison of Hyaluronidase and Dexametasone in Reduction of Postoperative Edema

July 15, 2022 updated by: Onur Koç, Hacettepe University

Comparison of the Effects of Hyaluronidase and Dexamethasone on Reduction of Postoperative Edema in Impacted Wisdom Teeth Surgery

The present study is designed to reveal effectiveness of hyaluronidase and dexamethasone on reduction of postoperative edema, pain, trismus, and infection. For this purpose, 60 participants with symmetrical mandibular wisdom teeth enrolled the present study. All measurements and evaluations were performed before and 1, 2, 3, and 7 days later the operation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Cyprus
      • Nicosia, Cyprus, 99138
        • Near East University
  • Turkey
    • Sıhhiye
      • Ankara, Sıhhiye, Turkey, 06100
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • symmetrical mandibular wisdom teeth with bone retention
  • patients who are signed informed consent and acceptance of study involvement forms

Exclusion Criteria:

  • existence of any systemic disease
  • existence of any periodical drug intake
  • existence of difference in operation times of right and left impacted wisdom teeth extractions more than 5 minutes
  • existence of pregnancy
  • existence of breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: hyaluronidase
Drug: Hyaluronidase Injection mesomedica
injection of 150 IU hyaluronidase to perioperative region, submucosally.
No Intervention: hyaluronidase control
Experimental: dexamethasone
Drug: Dexamethasone dekort
injection of 8 mg dexamethasone to perioperative region, submucosally.
No Intervention: dexamethasone control

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
evaluation of the increase of edema in postoperative 1. day using a measuring tape in hyaluronidase experimental group
Time Frame: postoperative 1. day
preoperative edema amount was subtracted from edema amount in 1. day in hyaluronidase experimental group
postoperative 1. day
evaluation of the increase of edema in postoperative 2. day using a measuring tape in hyaluronidase experimental group
Time Frame: postoperative 2. day
preoperative edema amount was subtracted from edema amount in 2. day in hyaluronidase experimental group
postoperative 2. day
evaluation of the increase of edema in postoperative 3. day using a measuring tape in hyaluronidase experimental group
Time Frame: postoperative 3. day
preoperative edema amount was subtracted from edema amount in 3. day in hyaluronidase experimental group
postoperative 3. day
evaluation of the increase of edema in postoperative 7. day using a measuring tape in hyaluronidase experimental group
Time Frame: postoperative 7. day
preoperative edema amount was subtracted from edema amount in 7. day in hyaluronidase experimental group
postoperative 7. day
evaluation of the increase of edema in postoperative 1. day using a measuring tape in hyaluronidase control group
Time Frame: postoperative 1. day
preoperative edema amount was subtracted from edema amount in 1. day in hyaluronidase control group
postoperative 1. day
evaluation of the increase of edema in postoperative 2. day using a measuring tape in hyaluronidase control group
Time Frame: postoperative 2. day
preoperative edema amount was subtracted from edema amount in 2. day in hyaluronidase control group
postoperative 2. day
evaluation of the increase of edema in postoperative 3. day using a measuring tape in hyaluronidase control group
Time Frame: postoperative 3. day
preoperative edema amount was subtracted from edema amount in 3. day in hyaluronidase control group
postoperative 3. day
evaluation of the increase of edema in postoperative 7. day using a measuring tape in hyaluronidase control group
Time Frame: postoperative 7. day
preoperative edema amount was subtracted from edema amount in 7. day in hyaluronidase control group
postoperative 7. day
evaluation of the increase of edema in postoperative 1. day using a measuring tape in dexamethasone experimental group
Time Frame: postoperative 1. day
preoperative edema amount was subtracted from edema amount in 1. day in dexamethasone experimental group
postoperative 1. day
evaluation of the increase of edema in postoperative 2. day using a measuring tape in dexamethasone experimental group
Time Frame: postoperative 2. day
preoperative edema amount was subtracted from edema amount in 2. day in dexamethasone experimental group
postoperative 2. day
evaluation of the increase of edema in postoperative 3. day using a measuring tape in dexamethasone experimental group
Time Frame: postoperative 3. day
preoperative edema amount was subtracted from edema amount in 3. day in dexamethasone experimental group
postoperative 3. day
evaluation of the increase of edema in postoperative 7. day using a measuring tape in dexamethasone experimental group
Time Frame: postoperative 7. day
preoperative edema amount was subtracted from edema amount in 7. day in dexamethasone experimental group
postoperative 7. day
evaluation of the increase of edema in postoperative 1. day using a measuring tape in dexamethasone control group
Time Frame: postoperative 1. day
preoperative edema amount was subtracted from edema amount in 1. day in dexamethasone controlgroup
postoperative 1. day
evaluation of the increase of edema in postoperative 2. day using a measuring tape in dexamethasone control group
Time Frame: postoperative 2. day
preoperative edema amount was subtracted from edema amount in 2. day in dexamethasone controlgroup
postoperative 2. day
evaluation of the increase of edema in postoperative 3. day using a measuring tape in dexamethasone control group
Time Frame: postoperative 3. day
preoperative edema amount was subtracted from edema amount in 3. day in dexamethasone controlgroup
postoperative 3. day
evaluation of the increase of edema in postoperative 7. day using a measuring tape in dexamethasone control group
Time Frame: postoperative 7. day
preoperative edema amount was subtracted from edema amount in 7. day in dexamethasone controlgroup
postoperative 7. day
evaluation of the difference in increase amounts of edema between hyaluronidase experimental and hyaluronidase control groups in postoperative 1. day using a measuring tape
Time Frame: postoperative 1. day
edema increase amount of hyaluronidase experimental group was compared with that of hyaluronidase control group in postoperative 1. day
postoperative 1. day
evaluation of the difference in increase amounts of edema between hyaluronidase experimental and hyaluronidase control groups in postoperative 2. day using a measuring tape
Time Frame: postoperative 2. day
edema increase amount of hyaluronidase experimental group was compared with that of hyaluronidase control group in postoperative 2. day
postoperative 2. day
evaluation of the difference in increase amounts of edema between hyaluronidase experimental and hyaluronidase control groups in postoperative 3. day using a measuring tape
Time Frame: postoperative 3. day
edema increase amount of hyaluronidase experimental group was compared with that of hyaluronidase control group in postoperative 3. day
postoperative 3. day
evaluation of the difference in increase amounts of edema between hyaluronidase experimental and hyaluronidase control groups in postoperative 7. day using a measuring tape
Time Frame: postoperative 7. day
edema increase amount of hyaluronidase experimental group was compared with that of hyaluronidase control group in postoperative 7. day
postoperative 7. day
evaluation of the difference in increase amounts of edema between dexamethasone experimental and dexamethasone control groups in postoperative 1. day using a measuring tape
Time Frame: postoperative 1. day
edema increase amount of dexamethasone experimental group was compared with that of dexamethasone control group in postoperative 1. day
postoperative 1. day
evaluation of the difference in increase amounts of edema between dexamethasone experimental and dexamethasone control groups in postoperative 2. day using a measuring tape
Time Frame: postoperative 2. day
edema increase amount of dexamethasone experimental group was compared with that of dexamethasone control group in postoperative 2. day
postoperative 2. day
evaluation of the difference in increase amounts of edema between dexamethasone experimental and dexamethasone control groups in postoperative 3. day using a measuring tape
Time Frame: postoperative 3. day
edema increase amount of dexamethasone experimental group was compared with that of dexamethasone control group in postoperative 3. day
postoperative 3. day
evaluation of the difference in increase amounts of edema between dexamethasone experimental and dexamethasone control groups in postoperative 7. day using a measuring tape
Time Frame: postoperative 7. day
edema increase amount of dexamethasone experimental group was compared with that of dexamethasone control group in postoperative 7. day
postoperative 7. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 1. day
Time Frame: postoperative 1. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 1. day
postoperative 1. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 2. day
Time Frame: postoperative 2. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 2. day
postoperative 2. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 3. day
Time Frame: postoperative 3. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 3. day
postoperative 3. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 4. day
Time Frame: postoperative 4. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 4. day
postoperative 4. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 5. day
Time Frame: postoperative 5. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 5. day
postoperative 5. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 6. day
Time Frame: postoperative 6. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 6. day
postoperative 6. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase experimental group in postoperative 7. day
Time Frame: postoperative 7. day
pain intensity of the patients in hyaluronidase experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 7. day
postoperative 7. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 1. day
Time Frame: postoperative 1. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 1. day
postoperative 1. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 2. day
Time Frame: postoperative 2. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 2. day
postoperative 2. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 3. day
Time Frame: postoperative 3. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 3. day
postoperative 3. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 4. day
Time Frame: postoperative 4. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 4. day
postoperative 4. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 5. day
Time Frame: postoperative 5. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 5. day
postoperative 5. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 6. day
Time Frame: postoperative 6. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 6. day
postoperative 6. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in hyaluronidase control group in postoperative 7. day
Time Frame: postoperative 7. day
pain intensity of the patients in hyaluronidase control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 7. day
postoperative 7. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 1. day
Time Frame: postoperative 1. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 1. day
postoperative 1. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 2. day
Time Frame: postoperative 2. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 2. day
postoperative 2. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 3. day
Time Frame: postoperative 3. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 3. day
postoperative 3. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 4. day
Time Frame: postoperative 4. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 4. day
postoperative 4. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 5. day
Time Frame: postoperative 5. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 5. day
postoperative 5. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 6. day
Time Frame: postoperative 6. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 6. day
postoperative 6. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone experimental group in postoperative 7. day
Time Frame: postoperative 7. day
pain intensity of the patients in dexamethasone experimental group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 7. day
postoperative 7. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 1. day
Time Frame: postoperative 1. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 1. day
postoperative 1. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 2. day
Time Frame: postoperative 2. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 2. day
postoperative 2. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 3. day
Time Frame: postoperative 3. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 3. day
postoperative 3. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 4. day
Time Frame: postoperative 4. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 4. day
postoperative 4. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 5. day
Time Frame: postoperative 5. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 5. day
postoperative 5. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 6. day
Time Frame: postoperative 6. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 6. day
postoperative 6. day
evaluation of the pain using visual analog scale (VAS) and daily count of NSAİ drug intake in dexamethasone control group in postoperative 7. day
Time Frame: postoperative 7. day
pain intensity of the patients in dexamethasone control group was assessed using visual analog scale (VAS) and daily count of NSAİ drug intake in postoperative 7. day
postoperative 7. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase experimental group preoperatively.
Time Frame: preoperative
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
preoperative
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase experimental group in postoperative 1. day.
Time Frame: postoperative 1. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 1. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase experimental group in postoperative 2. day.
Time Frame: postoperative 2. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 2. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase experimental group in postoperative 3. day.
Time Frame: postoperative 3. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 3. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase experimental group in postoperative 7. day.
Time Frame: postoperative 7. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 7. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase control group preoperatively.
Time Frame: preoperative
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
preoperative
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase control group in postoperative 1. day.
Time Frame: postoperative 1. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 1. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase control group in postoperative 2. day.
Time Frame: postoperative 2. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 2. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase control group in postoperative 3. day.
Time Frame: postoperative 3. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 3. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of hyaluronidase control group in postoperative 7. day.
Time Frame: postoperative 7. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 7. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone experimental group preoperatively.
Time Frame: preoperative
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
preoperative
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone experimental group in postoperative 1. day.
Time Frame: postoperative 1. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 1. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone experimental group in postoperative 2. day.
Time Frame: postoperative 2. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 2. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone experimental group in postoperative 3. day.
Time Frame: postoperative 3. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 3. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone experimental group in postoperative 7. day.
Time Frame: postoperative 7. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 7. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone control group preoperatively.
Time Frame: preoperative
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
preoperative
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone control group in postoperative 1. day.
Time Frame: postoperative 1. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 1. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone control group in postoperative 2. day.
Time Frame: postoperative 2. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 2. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone control group in postoperative 3. day.
Time Frame: postoperative 3. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 3. day
evaluation of trismus using a ruler, which measures the opening between mandibular and maxillary right first incisors of dexamethasone control group in postoperative 7. day.
Time Frame: postoperative 7. day
amount of trismus is revealed measuring the distance between the tips of incisal edges of mandibular and maxillary right first incisors using a ruler
postoperative 7. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase experimental group preoperatively.
Time Frame: preoperative
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
preoperative
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase experimental group in postoperative 1. day.
Time Frame: postoperative 1. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 1. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase experimental group in postoperative 2. day.
Time Frame: postoperative 2. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 2. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase experimental group in postoperative 3. day.
Time Frame: postoperative 3. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 3. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase experimental group in postoperative 7. day.
Time Frame: postoperative 7. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 7. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase control group preoperatively.
Time Frame: preoperative
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
preoperative
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase control group in postoperative 1. day.
Time Frame: postoperative 1. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 1. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase control group in postoperative 2. day.
Time Frame: postoperative 2. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 2. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase control group in postoperative 3. day.
Time Frame: postoperative 3. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 3. day
evaluation of infection in operation site via determination of infection signs in physical examination of hyaluronidase control group in postoperative 7. day.
Time Frame: postoperative 7. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 7. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone experimental group preoperatively.
Time Frame: preoperative
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
preoperative
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone experimental group in postoperative 1. day
Time Frame: postoperative 1. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 1. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone experimental group in postoperative 2. day
Time Frame: postoperative 2. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 2. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone experimental group in postoperative 3. day
Time Frame: postoperative 3. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 3. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone experimental group in postoperative 7. day
Time Frame: postoperative 7. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 7. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone control group preoperatively.
Time Frame: preoperatively
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
preoperatively
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone control group in postoperative 1. day
Time Frame: postoperative 1. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 1. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone control group in postoperative 2. day
Time Frame: postoperative 2. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 2. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone control group in postoperative 3. day
Time Frame: postoperative 3. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 3. day
evaluation of infection in operation site via determination of infection signs in physical examination of dexamethasone control group in postoperative 7. day
Time Frame: postoperative 7. day
existence of infection signs were determined using physical examination method. if the count of + signs are more than half of total amount of determined signs, the evaluation is accepted as (+) infected.
postoperative 7. day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hacettepe University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 13, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 20, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 20, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • YDU/2019//74-921

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings